A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer

Phase 3

Completed

• Conditions: Small Cell Lung Cancer
• Interventions: Drug: IP

• Registration Number: NCT00349492
• Lead Sponsor: Clinical Research Center for Solid Tumor, Korea

Brief Summary

This study is a randomized, multi-center clinical trial. Patients are stratified according to performance status (ECOG 0, 1 vs 2) and institution. Patients are randomized to 1 of 2 treatment arms.

Arm A: Patients receive etoposide IV on days 1, 2, 3 and cisplatin IV on day 1. Courses repeat every 3 weeks Arm B: Patients receive irinotecan IV on days 1, 8 and cisplatin IV on day 1. Coursed repeated every 3 weeks

Treatment in both arms continues for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1.5 years

Detailed Description

Not available

Study Timeline

• Study Start: 2006-06
• Study First Submitted: 2006-07-05
• Study First Submitted QC: 2006-07-05
• Study First Posted: 2006-07-07
• Primary Completion: 2011-12
• Status Verified: 2012-03
• Study Completion: 2013-10
• Last Update Submitted: 2013-12-03
• Last Update Posted: 2013-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 372

Inclusion Criteria

• Histologically or cytologically diagnosed small cell lung cancer
• Extensive disease (distant metastasis, contralateral hilar lymph node involvement, or cytologically confirmed malignant pleural effusion)
• If patients have brain metastasis with neurological symptom, they should be stabilized neurologically with prior radiotherapy or surgery for the brain metastasis (no neurologic symptom in progress and without further steroid treatment)
• No prior chemotherapy, immunotherapy, surgery or radiotherapy for small cell lung cancer (Local radiotherapy for brain or bone metastasis with symptom is permitted, in which case patients can be enrolled in this study when they have recovered from toxicity of radiotherapy)
• One or more measurable disease by RECIST criteria
• at least 18 years of age
• Performance status of 0, 1 and 2 on the Eastern Cooperative Oncology Group (ECOG) criteria
• Adequate hematologic (neutrophil count >= 1,500/uL, platelets >= 100,000/uL), hepatic (transaminase =< upper normal limit(UNL)x2.5, bilirubin level =< UNLx1.5), and renal (creatinine =< UNL) function
• Informed consent from patient which conforms to Institutional Review Board

Exclusion Criteria

• History of cured basal cell carcinoma or cured uterine cervical malignancy except for carcinoma in situ within 5 years
• Medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease
• Uncontrolled serious infection
• Enrollment in other study within 30 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EP	IP	etoposide + cisplatin

Primary Outcome Measures

Name	Time	Method
Overall survival	month

Secondary Outcome Measures

Name	Time	Method
Objective response rate	percent
Progression free survival	month
Safety profile	percent

Trial Locations

Locations (14)

Soonchunhyang University Bucheon Hospital; 🇰🇷 Bucheon-si, Korea, Republic of

Yeungnam University Hospital; 🇰🇷 Daegu, Korea, Republic of

Daegu Catholic University Hospital; 🇰🇷 Daegu, Korea, Republic of

Gyeongsang National University Hospital; 🇰🇷 Jinju, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-Si, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Kangbuk Samsung Hospital; 🇰🇷 Seoul, Korea, Republic of

Yonsei Cancer Center; 🇰🇷 Seoul, Korea, Republic of

Seoul Veterans Hospital; 🇰🇷 Seoul, Korea, Republic of

Kangnam St.Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

Scroll for more (4 remaining)